Visalytics
Visalytics
approved EB-2 (NIW)

Associate Professor

Pharmaceutics · Saudi Arabia · 2025-05-16

Processing Time
505 days
Decision Date
2025-05-16
This case is from a publicly available case study. Case studies tend to feature successful outcomes and may not reflect the full range of petition results.

Proposed Endeavor

The petitioner proposes to continue research in pharmaceutics, specifically focusing on drug nano-delivery systems and the development of smart, sustainable alternative drug dosage forms. This work utilizes pharmaceutical technology to improve the deliverability, targetability, efficacy, and safety of drugs. The intended impact is to address critical needs in drug formulation and patient care within the United States.

Framework Evaluation

3 of 3 criteria met
1 Substantial Merit and National Importance Met

The endeavor addresses critical needs in drug formulation and patient care, aligning with U.S. public health priorities.

2 Well-positioned to Advance the Endeavor Met

The petitioner's record of 14 publications, 2 patents, and nearly 1,000 citations demonstrates a high level of expertise and influence.

3 Waiver of Job Offer and Labor Certification Met

The petitioner's unique expertise in sustainable drug delivery systems makes his continued research indispensable to the U.S. scientific community.

Why This Petition Was Approved

The petition was approved based on the petitioner's significant contributions, including 14 peer-reviewed journal articles, 1 book chapter, and 2 granted patents. The work's impact is evidenced by 974 citations and the petitioner's role in the field as demonstrated by 36 peer reviews. These metrics satisfied the Dhanasar prongs by showing the national importance of the work and the petitioner's strong positioning to advance it.

Evidence

Evidence Types
Peer Reviewed Publications
Citations
Patents
Reference Letters Dependent
Judging Experience
Original Contributions
Government Alignment

Similar Cases

Scientist

Pharmaceuticals · India

WeGreened EB-2 (NIW) rfe approved
North Carolina 111 days 2025-02-08
The petitioner proposes to improve existing therapies by applying advanced pharmaceutical principles to commercialize biopharmaceuticals and pharmaceuticals. The work focuses on developing innovative drug solubility enhancement methods and non-invasive oral drug delivery systems to treat serious diseases like cancer, AIDS, and kidney failure.
View Case

Others

Pharmaceuticals · South Korea

WeGreened EB-2 (NIW) approved
54 days 2025-03-24
The petitioner proposes to continue her research in pharmaceutical science by integrating advanced technologies and computational approaches to develop novel drug candidates. Her work focuses on improving drug delivery systems to create more effective, affordable, and stable medications for chronic diseases including cancer, diabetes, hypertension, and neurodegenerative diseases.
View Case

Postdoctoral Researcher

Biotechnology · China

WeGreened EB-2 (NIW) approved
New York 169 days 2025-04-09
The petitioner proposes to continue research in the development of pharmacokinetics (PK) and pharmacodynamics (PD) studies, specifically focusing on the targeted delivery of anti-tumor and antimicrobial medications. This work involves synthesizing bioactive polymers, spatial metabolomics, and protein engineering to improve therapeutic efficacy. The endeavor aims to advance precision medications that reduce side effects for challenging diseases.
View Case

Scientist

Pharmaceuticals · India

WeGreened EB-2 (NIW) approved
North Carolina 132 days 2024-05-17
The petitioner proposes to continue her research in pharmaceutical sciences, specifically focusing on advancing drug repurposing and the development of nanoparticle-based delivery systems. Her work aims to create smarter, more efficient ways to deliver medications for critical diseases such as cancer and COVID-19. This research is intended to provide faster, cost-effective pathways for translating laboratory discoveries into viable clinical treatments.
View Case

Frequently Asked Questions

A approved EB-2 NIW (I-140) petition means USCIS determined the petitioner met the eligibility requirements. For appealed cases, "sustained" means the appeal reversed a prior denial. The petitioner can proceed to the next step in the immigration process.

Browse More Cases

More approved cases More Pharmaceuticals cases More cases from Saudi Arabia

Case data sourced from publicly available petition decisions and case studies. Decision date: 2025-05-16.

Browse all cases
View Original

At a Glance

Outcome approved
Processing 505 days
Criteria Met 3 / 3
Evidence Types 7

EB-2 (NIW) Case Data

Scraped Case Data

Total Cases 3,895
Success Rate 54.2%
Sustained 2,112
Dismissed 1,687

Related Pages

EB-2 (NIW) Overview EB-2 (NIW) in Saudi Arabia All EB-2 (NIW) Cases EB-2 (NIW) Dashboard Endeavor Search

Get Case Insights

Compare your profile against thousands of real petition outcomes. Join the waitlist for personalized analysis.

Join Waitlist